Information Provided By: 
Fly News Breaks for August 15, 2018
GILD
Aug 15, 2018 | 08:57 EDT
RBC Capital analyst Brian Abrahams kept his Outperform rating and $90 price target on Gilead, saying the company's purchased FDA Priority Review vouchers may be "underappreciated" by the Street. The analyst notes that two of them remain unused and may be deployed for use in filgotinib, Descovy for PrEP, and/or selonsertib, potentially adding about $2 in upside to his price target if used successfully.
News For GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
